期刊
ONCOLOGIST
卷 10, 期 4, 页码 250-261出版社
WILEY
DOI: 10.1634/theoncologist.10-4-250
关键词
fluorouracil; irinotecan; oxaliplatin; bevacizumab; cetuximab; vascular endothelial growth factor; VEGF
类别
Fluorouracil (FU) has been the mainstay of treatment for metastatic colorectal cancer (mCRC) for many years. However, in recent years, newer chemotherapeutic agents, particularly irinotecan (Campostar (R); Pfizer Pharmaceuticals, New York, NY, http://www.prizer.com) and more recently oxaliplatin (Eloxatin (R); Sanofi-Aventis Inc., New York, NY, http://www.sanori-aventis.com), have been shown to improve survival in combination with FU-based therapies. These agents were therefore incorporated into first- and second-line treatment strategies. The development of targeted agents that are tumor specific with better toxicity profiles than chemotherapeutic agents has widened the spectrum of therapies for this disease. The U.S. Food and Drug Administration (FDA) recently approved two targeted agents for treating mCRC: an antivascular endothelial growth factor monoclonal antibody (mAb), beva-cizumab (Avastin (R); Genentech, Inc., South San Francisco, CA, http://www.gene.com), in combination with first-line 5-FU-based chemotherapy regimens and the human epidermal growth factor receptor (HER-1/ EGFR)-targeted mAb cetuximab (Erbitux (R); ImClone Systems, Inc., New York, NY, http://www.imclone.com) as monotherapy or in combination with irinotecan as second-line therapy in refractory cancer. These newer, more effective agents are improving clinical outcome for patients with mCRC. However, as the number of agents has increased, choosing the most effective treatment strategy has become increasingly complex. This review discusses the role of the individual agents in the treatment of mCRC and identifies the most effective regimens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据